Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.

Celecoxib atop PPI bests naproxen in cutting recurrent GI bleeds

Pearl Toh
10 May 2017

Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.

Current guidelines provide conflicting recommendations for this group of high-risk patients who continue to require NSAIDs, according to the researchers. There were also concerns that “the superior gastric safety of COX-2**-selective NSAIDs over nonselective NSAIDs might disappear with the concomitant use of aspirin.”

“Contrary to present guidelines, we found that naproxen cannot be recommended to these high-risk patients despite its perceived CV benefit,” they claimed.

Of the 45 cases of recurrent upper GI bleeding identified by an adjudication committee, 14 cases were reported in the celecoxib group compared with 31 cases in the naproxen group. None of them had recurrent Helicobacter pylori infection. [Lancet 2017;doi:10.1016/S0140-6736(17)30981-9]

At 18 months, recurrent upper GI bleeding occurred in a significantly lower proportion of patients in the celecoxib group compared with the naproxen group (cumulative incidence, 5.6 percent vs 12.3 percent; p=0.008, and crude hazard ratio [HR], 0.44; p=0.01). According to the researchers, the HR remained the same after adjusting for concomitant aspirin use.

“Importantly, these high-risk patients should avoid using naproxen because even cotherapy with [PPI] does not adequately prevent recurrent bleeding,” they added.

Although the researchers noted that the study was not powered to evaluate CV safety of NSAIDs, no statistically significant difference was found between the two groups (cumulative incidence of CV events, 4.4 percent vs 5.5 percent; p=0.543, and crude HR, 0.78; p=0.544).

Excluding those who had reached study endpoints, the proportion of patients who discontinued treatment due to adverse events was similar in both celecoxib and naproxen groups (8 percent [n=21] vs 7 percent [n=17]). There was no death related to the study drugs.

The single-centre, double-blind, double-dummy trial enrolled patients with cardiothrombotic diseases and arthritis who presented with upper GI bleeding and who required concomitant NSAIDs and aspirin. After ulcer healing, 514 patients (54 percent males) negative for H. pylori were randomized on a 1:1 ratio to receive esomeprazole 100 mg once daily plus either celecoxib 100 mg twice daily or naproxen 500 mg twice daily for 18 months. All patients continued with aspirin 80 mg once daily.

“Avoidance of all NSAIDs will be the safest approach in these high-risk patients, but in patients who continue to require concomitant NSAIDs and aspirin, celecoxib plus a [PPI] encompass the least risk of recurrent upper [GI] bleeding,” said the researchers.

“From a GI perspective, naproxen is known to be riskier than celecoxib,” said Drs Patricia McGettigan and Anne-Marie Schjerning Olsen of Queen Mary University of London, UK, and Copenhagen University Hospital Herlev and Gentofte in Denmark, respectively in a separate commentary. “However, the superiority [of celecoxib] is relative. Neither option was safe.” [Lancet 2017;doi:10.1016/S0140-6736(17)30980-7

“The trial’s lost opportunity to fully inform guidelines is its failure to include a non-NSAID treatment group [in aspirin users],” they continued. “[Therefore, clinicians] are left to make a lesser of two evils recommendation as opposed to knowing the excess risk of either NSAID over simple analgesia [without NSAID].”

    

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.